Cleistanthin A inhibits the invasion and metastasis of human melanoma cells by inhibiting the expression of matrix metallopeptidase‑2 and ‑9

Pan,Sheng; Cai,Hengji; Gu,Lixiong; Cao,Shuanglin

doi:10.3892/ol.2017.6917

Cleistanthin A inhibits the invasion and metastasis of human melanoma cells by inhibiting the expression of matrix metallopeptidase‑2 and ‑9

Authors:
- Sheng Pan
- Hengji Cai
- Lixiong Gu
- Shuanglin Cao
View Affiliations

Affiliations: Department of Dermatology and Venereology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: September 8, 2017 https://doi.org/10.3892/ol.2017.6917
Pages: 6217-6223

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been demonstrated that numerous types of metastatic cancer overexpress vacuolar‑type H+ (V)‑ATPases. It may be possible to inhibit the growth and metastasis of human cancer cells by inhibiting V‑ATPases. It was previously reported that diphyllin, a novel V‑ATPase inhibitor, can inhibit the migration and invasion of SGC7901 human gastric cancer cells; however, the effects of cleistanthin A (CA), a diphyllin glycoside, on melanoma cells has not been demonstrated. The present study aimed to investigate the effect of CA as a V‑ATPase inhibitor and its effects on the invasion and metastasis of A375 cells. The results of an MTT assay in the present study indicated that the growth inhibition of A375 cells by CA was induced in a dose‑ and time‑dependent manner; however, A375 cell viability was not significantly affected by low concentrations (0.03, 0.1 and 0.3 µM) after 24 h. Similar results were obtained by viable cell counting with trypan blue. Therefore, these concentrations of CA were selected for the treatment of A375 cells in further experiments. It was demonstrated that CA inhibited the expression of V‑ATPases in a dose‑dependent manner and decreased the internal pH level of A375 cells. Alterations to the lysosomal pH were associated with the CA concentration. Furthermore, CA treatment induced a significant decrease in cell migration and invasion, as demonstrated with wound‑healing and Transwell assays. Gelatin zymography and western blot analysis demonstrated that the expression levels of matrix metallopeptidase (MMP)‑2 and ‑9 decreased following CA treatment. Therefore, CA can be characterized as a novel V‑ATPase inhibitor for the treatment of melanoma that may inhibit invasion and metastasis by downregulating the expression of MMP‑2 and ‑9.

View Figures

View References

1	Liu J, Fukunaga-Kalabis M, Li L and Herlyn M: Developmental pathways activated in melanocytes and melanoma. Arch Biochem Biophys. 563:13–21. 2014. View Article : Google Scholar : PubMed/NCBI
2	De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, et al: pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 127:207–219. 2010. View Article : Google Scholar : PubMed/NCBI
3	Chiche J, Brahimi-Horn MC and Pouysségur J: Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J Cell Mol Med. 14:771–794. 2010. View Article : Google Scholar : PubMed/NCBI
4	Vaupel P, Kallinowski F and Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res. 49:6449–6465. 1989.PubMed/NCBI
5	Harguindey S, Orive G, Pedraz Luis J, Paradiso A and Reshkin SJ: The role of pH dynamics and the Na⁺/H⁺ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin-one single nature. Biochim Biophys Acta. 1756:1–24. 2005.PubMed/NCBI
6	Rofstad EK: Microenvironment-induced cancer metastasis. Int J Radiat Biol. 76:589–605. 2000. View Article : Google Scholar : PubMed/NCBI
7	Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2:38–47. 2002. View Article : Google Scholar : PubMed/NCBI
8	Mason SD and Joyce JA: Proteolytic networks in cancer. Trends Cell Biol. 21:228–237. 2011. View Article : Google Scholar : PubMed/NCBI
9	Wiedmann RM, von Schwarzenberg K, Palamidessi A, Schreiner L, Kubisch R, Liebl J, Schempp C, Trauner D, Vereb G, Zahler S, et al: The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. Cancer Res. 72:5976–5987. 2012. View Article : Google Scholar : PubMed/NCBI
10	Fais S, De Milito A, You H and Qin W: Targeting vacuolar H⁺-ATPases as a new strategy against cancer. Cancer Res. 67:10627–10630. 2007. View Article : Google Scholar : PubMed/NCBI
11	Chung C, Mader CC, Schmitz JC, Atladottir J, Fitchev P, Cornwell ML, Koleske AJ, Crawford SE and Gorelick F: The vacuolar-ATPase modulates matrix metalloproteinase isoforms in human pancreatic cancer. Lab Invest. 91:732–743. 2011. View Article : Google Scholar : PubMed/NCBI
12	Fortini ME and Bilder D: Endocytic regulation of Notch signaling. Curr Opin Genet Dev. 19:323–328. 2009. View Article : Google Scholar : PubMed/NCBI
13	Vaccari T, Duchi S, Cortese K, Tacchetti C and Bilder D: The vacuolar ATPase is required for physiological as well as pathological activation of the Notch receptor. Development. 137:1825–1832. 2010. View Article : Google Scholar : PubMed/NCBI
14	Zhang Z, Ma J, Zhu L and Zhao Y: Synthesis and identification of cytotoxic diphyllin glycosides as vacuolar H(+)-ATPase inhibitors. Eur J Med Chem. 82:466–471. 2014. View Article : Google Scholar : PubMed/NCBI
15	Shen W, Zou X, Chen M, Liu P, Shen Y, Huang S, Guo H and Zhang L: Effects of diphyllin as a novel V-ATPase inhibitor on gastric adenocarcinoma. Eur J Pharmacol. 667:330–338. 2011. View Article : Google Scholar : PubMed/NCBI
16	Vandooren J, Geurts N, Martens E, Van den Steen PE and Opdenakker G: Zymography methods for visualizing hydrolytic enzymes. Nat Methods. 10:211–220. 2013. View Article : Google Scholar : PubMed/NCBI
17	Lu X, Qin W, Li J, Tan N, Pan D, Zhang H, Xie L, Yao G, Shu H, Yao M, et al: The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res. 65:6843–6849. 2005. View Article : Google Scholar : PubMed/NCBI
18	Sørensen MG, Henriksen K, Neutzsky-Wulff AV, Dziegiel MH and Karsdal MA: Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Miner Res. 22:1640–1648. 2007. View Article : Google Scholar : PubMed/NCBI
19	Yu W, Wang L, Wang Y, Xu X, Zou P, Gong M, Zheng J, You J, Wang H, Mei F and Pei F: A novel tumor metastasis suppressor gene LASS2/TMSG1 interacts with vacuolar ATPase through its homeodomain. J Cell Biochem. 114:570–583. 2013. View Article : Google Scholar : PubMed/NCBI
20	Takahashi M, Tsunoda T, Seiki M, Nakamura Y and Furukawa Y: Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene. 21:5861–5867. 2002. View Article : Google Scholar : PubMed/NCBI
21	Ma Y, Zou F, Xiong J, Wan W, Yin L, Li X, Bei Z, Yuan L, Meng S, Wang J and Song G: Effect of Matrine on HPAC cell migration by down-regulating the expression of MT1-MMP via Wnt signaling. Cancer Cell Int. 15:592015. View Article : Google Scholar : PubMed/NCBI
22	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
23	Itoh Y and Seiki M: MT1-MMP: A potent modifier of pericellular microenvironment. J Cell Physiol. 206:1–8. 2006. View Article : Google Scholar : PubMed/NCBI
24	Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H and Seiki M: Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol. 153:893–904. 2001. View Article : Google Scholar : PubMed/NCBI
25	Deryugina EI, Ratnikov BI, Postnova TI, Rozanov DV and Strongin AY: Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase. J Biol Chem. 277:9749–9756. 2002. View Article : Google Scholar : PubMed/NCBI
26	Sato H, Takino T and Miyamori H: Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and metastasis. Cancer Sci. 96:212–217. 2005. View Article : Google Scholar : PubMed/NCBI
27	Seiki M: Membrane-type 1 matrix metalloproteinase: A key enzyme for tumor invasion. Cancer Lett. 194:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
28	Knopfová L, Beneš P, Pekarčíková L, Hermanová M, Masařík M, Pernicová Z, Souček K and Smarda J: c-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: Implications for matrix-dependent breast cancer cell invasion and metastasis. Mol Cancer. 11:152012. View Article : Google Scholar : PubMed/NCBI
29	Yousef EM, Tahir MR, St-Pierre Y and Gaboury LA: MMP-9 expression varies according to molecular subtypes of breast cancer. BMC Cancer. 14:6092014. View Article : Google Scholar : PubMed/NCBI